Pharmaceutical - Financial, Licensing

Filter

Current filters:

FinancialLicensing

Popular Filters

1 to 25 of 78 results

Glenmark gets $4 million milestone in Forest collaboration

Glenmark gets $4 million milestone in Forest collaboration

27-03-2014

Indian drugmaker Glenmark Pharmaceuticals has informed the Stock Exchange today that the company through…

FinancialForest LaboratoriesGlenmark PharmaceuticalsInflammatory diseasesLicensingPharmaceutical

Merck returns rights to ridaforolimus to Ariad, whose 4th-qtr net loss widens

Merck returns rights to ridaforolimus to Ariad, whose 4th-qtr net loss widens

26-02-2014

US pharma giant Merck & Co has told partner Ariad Pharmaceutical that it is terminating its license agreement…

Ariad PharmaceuticalsFinancialLicensingMerck & CoOncologyPharmaceuticalridaforolimus

$20 million milestones for MacroGenics from Servier

$20 million milestones for MacroGenics from Servier

06-02-2014

Servier, France’s largest privately‐held pharmaceutical company, has exercised its exclusive option…

FinancialHematologyLicensingMacroGenicsMGD006OncologyPharmaceuticalServier

Forest spends $240 million for US rights to Saphris; streamlines operations

02-12-2013

US drugmaker Forest Laboratories is acquiring exclusive rights in the USA for Saphris (asenapine) sublingual…

FinancialForest LaboratoriesLicensingMerck & CoNeurologicalNorth AmericaPharmaceuticalSaphrisUSA

Baxter buys exclusive rights to CTI’s cancer drug pacritinib

18-11-2013

USA-based companies Baxter International and Cell Therapeutics have entered into an exclusive worldwide…

Baxter InternationalCell TherapeuticsFinancialGlobalLicensingOncologypacritinibPharmaceutical

Immunocore makes progress in deal with GSK

Immunocore makes progress in deal with GSK

07-11-2013

UK-based biotech firm Immunocore has achieved its first milestone in its major research and licensing…

EuropeFinancialGlaxoSmithKlineImmunocoreLicensingOncologyPharmaceuticalResearchUK

PDL BioPharma secures royalties on diabetes products in $240m deal

PDL BioPharma secures royalties on diabetes products in $240m deal

22-10-2013

PDL BioPharma has acquired the rights to receive royalties and milestones payable on sales of Type 2…

DepomedDiabetesFinancialGlumetzaInvokanaJanumetLicensingmetforminNorth AmericaPDL BioPharmaPharmaceutical

Astellas links with Mitokyne on mitochondria-related therapies

Astellas links with Mitokyne on mitochondria-related therapies

07-10-2013

Japanese drug major Astellas Pharma and USA-based start-up Mitokyne have entered into an exclusive R&D…

Astellas PharmaFinancialLicensingMergers & AcquisitionsMitokynePharmaceuticalResearch

Isis earns milestone payments from GlaxoSmithKline

Isis earns milestone payments from GlaxoSmithKline

07-10-2013

US biotech firm Isis Pharmaceuticals says that UK pharma giant GlaxoSmithKline has added a development…

BiotechnologyFinancialGlaxoSmithKlineIsis PharmaceuticalsLicensingPharmaceuticalRare diseases

First-half 2013 sees fall in licensing, says Evaluate

20-09-2013

Despite a positive start to the year characterized by healthy initial public offering (IPO) activity…

FinancialLicensingMergers & AcquisitionsPharmaceutical

DRI Capital raises $1.45 billion for Drug Royalty III

09-09-2013

DRI Capital, a global leader in the acquisition of health care royalties, today (September 9) announced…

FinancialLicensingPharmaceutical

Karo Bio gets first milestone in Pfizer collaboration

06-09-2013

Under its collaboration with US pharma behemoth Pfizer (NYSE: PFE), Sweden's Karo Bio (STO: KARO) says…

Anti-Arthritics/RheumaticsDermatologicalsFinancialKaro BioLicensingNeurologicalPfizerPharmaceuticalResearch

Repligen gets first milestone under SMA deal with Pfizer

05-09-2013

USA-based Repligen (Nasdaq: RGEN) says it has received a $1 million milestone payment from global drugs…

FinancialLicensingPfizerPharmaceuticalRare diseasesRepligen

ObsEva gets funding and makes deal with Merck Serono

30-08-2013

Geneva, Switzerland-based ObsEva says that it has closed a 32 million Swiss franc ($34.8 million) -A…

FinancialLicensingMerck KGaAMerck SeronoObsEvaPharmaceuticalWomen's Health

Nektar hedges bets on deal with AstraZeneca

12-08-2013

Along with presenting second-quarter financial results, Howard Robin, president and chief executive of…

AstraZenecaFinancialGastro-intestinalsLicensingnaloxegolNektar TherapeuticsPharmaceutical

Quest Diagnostics sells ibrutinib royalty rights for $485 million

19-07-2013

USA-based diagnostic services firm Quest Diagnostics (NYSE: DGX) says it has completed the sale of its…

FinancialibrutinibLicensingOncologyPharmaceuticalQuest DiagnosticsRoyalty Pharma

Paladin and Bioniche officially close debt refinancing and Urocidin licensing deals

08-07-2013

Canadian companies Bioniche Life Sciences (TSX: BNC) and Paladin Labs (TSX: PLB) said on Friday (July…

Bioniche Life SciencesFinancialLicensingOncologyPaladin LabsPharmaceuticalUrocidin

NeuroVive signs deal with Isomerase Therapeutics; receives the first milestone from Sihuan

12-06-2013

Swedish mitochondrial medicine firm NeuroVive Pharmaceutical has signed a collaboration agreement with…

FinancialIsomerase TherapeuticsLicensingNeuroVivePharmaceuticalSihuan Pharmaceutical

Life Sciences IPOs have biggest month - May - in 13 years, reports Burrill

07-06-2013

A total of eight life sciences companies went public on US exchanges in May, the busiest month for initial…

BiotechnologyFinancialLicensingMergers & AcquisitionsPharmaceutical

GlaxoSmithKline buys rights to MorphoSys RA drug candidate for up to $577 million

04-06-2013

German biotech firm MorphoSys (FSE: MOR) yesterday (June 3) saw its shares leap as much as 6%, as it…

Anti-Arthritics/RheumaticsFinancialLicensingPharmaceutical

Alexza deal with Teva sets stage for Adasuve, say analysts

23-05-2013

USA-based Alexza Pharmaceuticals' (Nasdaq: ALXA) US marketing deal with Israel-headquartered Teva Pharmaceutical…

AdasuveAlexza PharmaceuticalAZ-002FinancialLicensingNeurologicalPharmaceuticalTeva Pharmaceutical Industries

Elan pays $1 billion for a 21% share of Theravance royalties on four respiratory programs

13-05-2013

US biotech firm Theravance (Nasdaq: THRX) has entered into a royalty participation agreement wherein…

Anoro ElliptaBiotechnologyBreo ElliptaElanFinancialGlaxoSmithKlineLicensingPharmaceuticalRespiratory and PulmonaryTheravance

Trevena and Forest Labs collaborate on TRV027 for acute heart failure

10-05-2013

US GPCR ligand drug developer Trevena and Forest Laboratories (NYSE: FRX) have entered into a collaborative…

Cardio-vascularFinancialForest LaboratoriesLicensingPharmaceuticalTrevenaTRV027

Regeneron acquires rights to two ophthalmology programs from Sanofi

03-05-2013

US biotech firm Regeneron Pharmaceuticals (Nasdaq: REGN) has expanded its ophthalmology portfolio by…

BiotechnologyEyleaFinancialLicensingOphthalmicsPharmaceuticalRegeneronSanofi

1 to 25 of 78 results

Back to top